Abstract
Radium-223 (Ra-223), strontium-89 (Sr-89), and samarium-153 (Sm-153) are radiopharmaceuticals approved in the United States and elsewhere for the treatment of painful skeletal metastases in select populations (Tables 30.1 and 30.2). The primary aim of this chapter is to provide a cohesive educational review of practice recommendations for these agents using guidelines from professional societies, prescribing information, and published observations.
References
Bayer. Xofigo prescribing information. 2016 [cited 2017 May 27]. Available from: http://labeling.bayerhealthcare.com/html/products/pi/Xofigo_PI.pdf.
GE. Metastron prescribing information. 2013 [cited 2017 May 27]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=020134.
Lantheus. Quadramet prescribing information. 2014. Available from: http://www.lantheus.com/products/overview/quadramet/.
USNRC. Code of Federal Regulations, Title 10, Part 35 (10 CFR Part 35) – Medical use of byproduct material. 2017 [cited 2017 Jun 04]. Available from: https://www.nrc.gov/reading-rm/doc-collections/cfr/part035/.
Larson RH, Henriksen G, Bruland ØS. Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning. 2003: United States patent US6635234 B1.
Henriksen G, et al. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44(2):252–9.
Nilsson S, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451–9.
Carrasquillo JA, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of (2)(2)(3)Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(9):1384–93.
Abou DS, et al. Whole-body and microenvironmental localization of radium-223 in naive and mouse models of prostate cancer metastasis. J Natl Cancer Inst. 2016;108(5):djv380.
Frankenberg-Schwager M, Frankenberg D. Rejoining of radiation-induced DNA double-strand breaks in yeast. In: Obe G, editor. Advances in mutagenesis research. Berlin: Springer; 1991. p. 1–25.
Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6(6):392–400.
Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.
Saad F, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306–16.
Lowrance WT, et al. Castration-resistant prostate cancer: AUA guideline amendment 2015. J Urol. 2016;195(5):1444–52.
Shore ND. When to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2016;14(1):26–9.
Modi D, et al. Radium-223 in heavily pretreated metastatic castrate-resistant prostate cancer. Clin Genitourin Cancer. 2016;14(5):373. e2–380.e2.
Cornford P, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.
Baldari S, et al. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: opinions and suggestions from an expert multidisciplinary panel. Crit Rev Oncol Hematol. 2017;113:43–51.
Umeweni N, Knight H, McVeigh G. NICE guidance on gadium-223 dichloride for hormone-relapsed prostate cancer with bone metastases. Lancet Oncol. 2016;17(3):275–6.
Crawford ED, et al. The role of therapeutic layering in optimizing treatment for patients with castration-resistant prostate cancer (prostate cancer radiographic assessments for detection of advanced recurrence II). Urology. 2017;104:150–9.
Bayer. Product Monograph Xofigo. Radium Ra 223 dichloride solution for injection. [Monograph] 2016 [cited 2017 Apr 02]. Available from: http://omr.bayer.ca/omr/online/xofigo-pm-en.pdf.
NLM, ClinicalTrials.gov. 2017.
Finkelstein S, et al. External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial. Int J Radiat Oncol Biol Phys. 2015;93(3):S20. [Abstract 1107].
USNRC. Revision to the National Institute of Standards and Technology standard for radium-223 and impact on dose calibration for the medical use of radium-223 dichloride. 2016 [cited 2017 Jun 18]. Available from: https://www.nrc.gov/docs/ML1526/ML15264B095.pdf.
Hague C, Logue JP. Clinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastases. Ther Adv Urol. 2016;8(3):175–80.
NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Prostate Cancer. Version 2.2017 2017 [cited 2017 Apr 02]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
Dauer LT, et al. Radiation safety considerations for the use of (2)(2)(3)RaCl(2) DE in men with castration-resistant prostate cancer. Health Phys. 2014;106(4):494–504.
Sartor O, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28(5):1090–7.
Benjegerdes KE, Brown SC, Housewright CD. Focal cutaneous squamous cell carcinoma following radium-223 extravasation. Proc (Bayl Univ Med Cent). 2017;30(1):78–9.
Brady D, Parker CC, O’Sullivan JM. Bone-targeting radiopharmaceuticals including radium-223. Cancer J. 2013;19(1):71–8.
Jong JM, et al. Radiopharmaceuticals for palliation of bone pain in patients with castration-resistant prostate cancer metastatic to bone: a systematic review. Eur Urol. 2016;70(3):416–26.
Nilsson S, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48(5):678–86.
Preston DF, Dusing RW. Therapy for painful skeletal metastases. In: Henkin RE, editor. Nuclear medicine. Philadelphia: Mosby Elsevier; 2006.
Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004;45(8):1358–65.
Nilsson S. Radionuclide therapies in prostate cancer: integrating radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer. Curr Oncol Rep. 2016;18(2):14.
Silberstein EB, et al. Society of Nuclear Medicine procedure guideline for palliative treatment of painful bone metastases. 2003 [cited 2017 May 27]. Available from: http://snmmi.files.cms-plus.com/docs/pg_ch25_0403.pdf.
Henkin RE, et al. ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. Clin Nucl Med. 2011;36(8):e72–80.
UCSD. Radionuclide Data Sheets. 2017 [cited 2017 Jun 04]. Available from: https://blink.ucsd.edu/safety/radiation/research/RUA/radionuclide.html.
Eary JF, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993;34(7):1031–6.
Tu SM, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357(9253):336–41.
Collins C, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993;34(11):1839–44.
Resche I, et al. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33(10):1583–91.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Murphy, R., Evangelista, L. (2018). Guidelines on Radioisotope Treatment of Bone Metastases in Prostate Cancer. In: Bombardieri, E., Seregni, E., Evangelista, L., Chiesa, C., Chiti, A. (eds) Clinical Applications of Nuclear Medicine Targeted Therapy . Springer, Cham. https://doi.org/10.1007/978-3-319-63067-0_30
Download citation
DOI: https://doi.org/10.1007/978-3-319-63067-0_30
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-63066-3
Online ISBN: 978-3-319-63067-0
eBook Packages: MedicineMedicine (R0)